KR20160013163A - 과민성 대장 증후군 진단을 예측하기 위한 경로 특이적 검정법 - Google Patents

과민성 대장 증후군 진단을 예측하기 위한 경로 특이적 검정법 Download PDF

Info

Publication number
KR20160013163A
KR20160013163A KR1020157036487A KR20157036487A KR20160013163A KR 20160013163 A KR20160013163 A KR 20160013163A KR 1020157036487 A KR1020157036487 A KR 1020157036487A KR 20157036487 A KR20157036487 A KR 20157036487A KR 20160013163 A KR20160013163 A KR 20160013163A
Authority
KR
South Korea
Prior art keywords
antibody
group
acid
compound
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157036487A
Other languages
English (en)
Korean (ko)
Inventor
파비욜라 셀바라즈
프레드 프린슨
샤라트 싱
Original Assignee
네스텍 소시에테아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네스텍 소시에테아노님 filed Critical 네스텍 소시에테아노님
Publication of KR20160013163A publication Critical patent/KR20160013163A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
KR1020157036487A 2013-05-24 2014-05-22 과민성 대장 증후군 진단을 예측하기 위한 경로 특이적 검정법 Ceased KR20160013163A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827506P 2013-05-24 2013-05-24
US61/827,506 2013-05-24
PCT/IB2014/061634 WO2014188377A2 (en) 2013-05-24 2014-05-22 Pathway specific assays for predicting irritable bowel syndrome diagnosis

Publications (1)

Publication Number Publication Date
KR20160013163A true KR20160013163A (ko) 2016-02-03

Family

ID=50884973

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157036487A Ceased KR20160013163A (ko) 2013-05-24 2014-05-22 과민성 대장 증후군 진단을 예측하기 위한 경로 특이적 검정법
KR1020157036482A Ceased KR20160010621A (ko) 2013-05-24 2014-05-22 과민성 대장 증후군의 진단을 위한 경로 특이적 마커

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157036482A Ceased KR20160010621A (ko) 2013-05-24 2014-05-22 과민성 대장 증후군의 진단을 위한 경로 특이적 마커

Country Status (14)

Country Link
US (5) US9891235B2 (https=)
EP (2) EP3004892B1 (https=)
JP (4) JP2016521683A (https=)
KR (2) KR20160013163A (https=)
CN (2) CN105579852B (https=)
AU (3) AU2014269961A1 (https=)
BR (2) BR112015029320A8 (https=)
CA (2) CA2912993A1 (https=)
HK (1) HK1223361A1 (https=)
IL (2) IL242595B (https=)
MX (1) MX367046B (https=)
RU (2) RU2015155590A (https=)
SG (2) SG11201509371XA (https=)
WO (2) WO2014188378A1 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521683A (ja) 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
JP6495256B2 (ja) 2013-06-21 2019-04-03 オンデック ピーティーワイ リミテッド 免疫療法組成物及びその使用
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
TWI688571B (zh) 2014-11-19 2020-03-21 英商Ｎｚｐ英國有限公司 化合物（四）
US10131688B2 (en) 2014-11-19 2018-11-20 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
JP2018501202A (ja) 2014-11-19 2018-01-18 ネステク ソシエテ アノニム セロトニン、トリプトファン、及びキヌレニンの代謝産物に対する抗体及びその使用
KR102526631B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
HK1244881A1 (zh) * 2014-12-02 2018-08-17 Société des Produits Nestlé S.A. 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
CN105987995A (zh) * 2015-02-04 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒
CN105987996A (zh) * 2015-02-09 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106399344B (zh) * 2016-06-01 2021-01-01 上海领潮生物新材料有限公司 一种vin-cdtb融合蛋白的制备方法
WO2018011691A1 (en) * 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
CN106188191A (zh) * 2016-07-13 2016-12-07 西安电子科技大学 基于gsh响应的诊治一体化有机分子探针及其制备方法
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US10428370B2 (en) 2016-09-15 2019-10-01 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
EP3512946A4 (en) * 2016-09-15 2020-04-08 Sun Genomics Inc. UNIVERSAL METHOD FOR EXTRACTING NUCLEIC ACID MOLECULES FROM A DIVERSE POPULATION OF ONE OR MORE TYPES OF MICROBES IN A SAMPLE
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
JP2020502126A (ja) 2016-12-14 2020-01-23 プロジェニティ， インコーポレイテッド 消化管疾病のｊａｋ阻害薬による治療
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
JP2020513280A (ja) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド 消化管疾病の免疫抑制剤による治療
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
CN110430801B (zh) 2016-12-14 2024-04-30 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3750168B1 (en) * 2018-02-09 2025-11-19 Metabolomic Diagnostics Limited A system and method of generating a model to detect, or predict the risk of, an outcome
EP3770606A4 (en) * 2018-03-19 2021-12-29 FUJIFILM Wako Pure Chemical Corporation Method for judging psychiatric disorder
EP3785033B1 (en) * 2018-04-24 2025-12-10 Universiteit Gent Intestinal biomarkers for intestinal health of poultry
AU2019278927A1 (en) 2018-06-01 2020-12-24 Bt Bidco, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
CA3101541A1 (en) * 2018-06-07 2019-12-12 4D Pharma Plc Method for stratifying ibs patients
CN110607335B (zh) * 2018-06-14 2021-08-03 中国科学院微生物研究所 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法
CN109324132A (zh) * 2018-10-31 2019-02-12 杭州佰辰医学检验所有限公司 高通量检测色氨酸及其代谢产物的试剂盒及其应用
US11488699B1 (en) 2018-12-09 2022-11-01 Cerner Innovation, Inc. Microbiota activity sensor and decision support tool
US11842795B1 (en) * 2018-12-17 2023-12-12 Cerner Innovation, Inc. Irritable bowel syndrome diagnostic sensor and decision support tool
FR3094492A1 (fr) * 2019-04-01 2020-10-02 Polyneuros Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique
WO2020201458A1 (en) * 2019-04-03 2020-10-08 4D Pharma Cork Limited Methods of diagnosing disease
JPWO2020213732A1 (ja) * 2019-04-18 2021-04-30 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) * 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
WO2020232262A1 (en) * 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
CN111351870A (zh) * 2019-12-03 2020-06-30 康美华大基因技术有限公司 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒
EP4085256B1 (en) 2020-01-27 2024-01-24 Immundiagnostik AG Test and in vitro diagnosis of irritable bowel syndrome
WO2021152586A1 (en) * 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114755313B (zh) * 2021-01-08 2024-08-30 复旦大学附属华山医院 包含尿液nad+代谢物的急性肾损伤标志物
CN115724779B (zh) * 2021-09-01 2024-03-29 四川大学 酰胺烷二硫化合物、其制备方法和用途
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
WO2023180899A1 (en) * 2022-03-21 2023-09-28 Swain Manish Kumar Device and method for detecting diarrhea
CN116381222A (zh) * 2023-03-23 2023-07-04 北京巴瑞医疗器械有限公司 一种血清素发光免疫检测方法及血清素检测试剂盒
CN116990498B (zh) * 2023-09-28 2024-08-09 山东大学齐鲁医院 血浆色氨酸代谢物在儿童偏头痛诊断中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
WO2001044274A1 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2005041896A2 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100094560A1 (en) 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8278057B2 (en) 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
US20120171672A1 (en) 2009-04-14 2012-07-05 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP3309556B1 (en) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
PH12012500850A1 (en) * 2009-10-30 2013-01-07 Prometheus Laboratories Inc Methods for diagnosing irritable bowel syndrome
CA2781654A1 (en) * 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
US8445215B1 (en) * 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
WO2012158831A1 (en) * 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
JP2015502740A (ja) * 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
MX360479B (es) 2012-10-05 2018-11-05 Nestec Sa Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
JP2016521683A (ja) 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
DK3078744T3 (da) * 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne

Also Published As

Publication number Publication date
WO2014188377A3 (en) 2015-03-05
MX367046B (es) 2019-08-02
US10338083B2 (en) 2019-07-02
US20180136233A1 (en) 2018-05-17
US20160139148A1 (en) 2016-05-19
US20180321259A1 (en) 2018-11-08
HK1223361A1 (zh) 2017-07-28
SG11201509370UA (en) 2015-12-30
US9891235B2 (en) 2018-02-13
CN105579852A (zh) 2016-05-11
BR112015029320A2 (pt) 2017-07-25
RU2015155590A (ru) 2017-06-29
IL242597B (en) 2019-02-28
EP3004892B1 (en) 2018-10-10
US9739786B2 (en) 2017-08-22
WO2014188378A1 (en) 2014-11-27
JP2016521683A (ja) 2016-07-25
CA2913108A1 (en) 2014-11-27
SG11201509371XA (en) 2015-12-30
HK1223416A1 (en) 2017-07-28
RU2015155552A (ru) 2017-06-27
US10036759B2 (en) 2018-07-31
IL242595B (en) 2019-01-31
CN105392780A (zh) 2016-03-09
JP2016520199A (ja) 2016-07-11
US20170307637A1 (en) 2017-10-26
WO2014188377A2 (en) 2014-11-27
CN105579852B (zh) 2017-12-01
JP2019194600A (ja) 2019-11-07
BR112015029318A2 (pt) 2017-07-25
AU2014269960B2 (en) 2018-05-10
EP3004892A1 (en) 2016-04-13
US20160130279A1 (en) 2016-05-12
JP2019151637A (ja) 2019-09-12
AU2014269960A1 (en) 2015-11-26
AU2014269961A1 (en) 2015-11-26
KR20160010621A (ko) 2016-01-27
BR112015029320A8 (pt) 2023-01-03
CA2912993A1 (en) 2014-11-27
EP3004068A2 (en) 2016-04-13
AU2018214104A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
KR20160013163A (ko) 과민성 대장 증후군 진단을 예측하기 위한 경로 특이적 검정법
KR20170080701A (ko) 세로토닌, 트립토판 및 키누레닌 대사산물에 대한 항체 및 그의 용도
EP2379601B1 (en) Anti-idiotype antibody against an antibody against the amyloid beta peptide
ES2428876T3 (es) Ensayo de anticuerpo antifármaco
RU2636822C2 (ru) Способ обнаружения мультиспецифического связывающего агента
US20220146501A1 (en) Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
JP2013513107A (ja) 自己抗体抗原結合を阻害するためのペプチド試薬及び方法
WO2018011691A1 (en) Competitive immunoassay methods
US20190339264A1 (en) Immunoassay controls and the use thereof
US20210405063A1 (en) Assay detection methods for vcam-1 and calprotectin
US20220283173A1 (en) Differential detection of viral and bacterial infections
JP7485755B2 (ja) アッセイ干渉物質を検出し、ダイナミックレンジを増大させる方法
FR2931481A1 (fr) Anticorps specifique de la lysine propionylee/butyrylee, son procede d'obtention et ses applications
JP2022540764A (ja) 抗ＴＮＦα生物製剤および抗薬剤抗体の検出
JP2022532385A (ja) 血中のＶＣＡＭ－１及びα２－マクログロブリンの検出のためのアッセイ方法
ES2472290A1 (es) Anticuerpos para la detección y cuantificación de agentes anticoagulantes
Cernoch et al. Production and analytical characterization of neopterin immunoreagents for biosensor developments
US20230160906A1 (en) Detection of anti-tnf alpha drug biologics and anti-drug antibodies
JP2005062114A (ja) 糖脂質の測定法、疾病検出方法及びキット

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190517

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190716

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210225

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210308

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210513

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210308

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20210225

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I